MyPeptideMatchCagriSema, a compounded combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide, studied in Phase 3 REDEFINE trials with approximately 22.7% body weight reduction at 68 weeks.
Peptide Blend
CagriSema, a compounded combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide, studied in Phase 3 REDEFINE trials with approximately 22.7% body weight reduction at 68 weeks.
No clinics in our directory yet. Browse all clinics.
Find a Peptide Clinic Near YouMyPeptideMatch.com does not provide medical advice. Always consult a qualified healthcare provider before starting any peptide therapy. Regulatory status may change.
Browse our directory of verified peptide therapy clinics.
Find a Clinic